Journal of Pediatric Neurology 2022; 20(06): 419-422
DOI: 10.1055/s-0042-1744359
Case Report

Abnormal Movement Following Transcobalamin II Deficiency Treatment Responding to Clonazepam: A Case Report

1   Division of Pediatric Neurology, Department of Neurosciences, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
,
Abdullah Hussain AlJefri
2   Department of Pediatric Oncology, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
,
1   Division of Pediatric Neurology, Department of Neurosciences, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
› Author Affiliations
Funding None.

Abstract

Transcobalamin II (TCII) is a transporter protein that facilitates cobalamin release from the bloodstream to the cell. Deficiency in TCII is an autosomal recessive disorder caused by a mutation in the TCN2 gene. Treatment with intramuscular injection of hydroxocobalamin is greatly effective in improving the symptoms of this disorder. However, abnormal involuntary movements can occur and have been reported in patients with cobalamin deficiency caused by nutritional deficiency. Though, it is rarely associated with the treatment of hereditary TCII deficiency. Here, we report such a case, aiming to alert practitioners treating hereditary TCII deficiency. A 2-year-old boy born to a consanguineous parents presented with failure to thrive, recurrent infection, and pancytopenia. His condition deteriorated rapidly, and his investigation was remarkable for pancytopenia, elevated methylmalonic acid, and myelodysplastic changes in the bone marrow. A flash whole-exome sequence confirmed the diagnosis of TCII deficiency. The patient began treatment with IM hydroxocobalamin, and on the second day, he developed an abnormal involuntary movement that was abated by clonazepam. Abnormal nonepileptic movements following IM hydroxocobalamin in a patient with TCII deficiency shows a remarkable response to clonazepam.



Publication History

Received: 19 June 2021

Accepted: 03 February 2022

Article published online:
25 April 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Grech V, Vella C, Mercieca V. Temporary myoclonus with treatment of congenital transcobalamin 2 deficiency. Pediatr Neurol 2001; 24 (01) 75-76
  • 2 Hakami N, Neiman PE, Canellos GP, Lazerson J. Neonatal megaloblastic anemia due to inherited transcobalamin II deficiency in two siblings. N Engl J Med 1971; 285 (21) 1163-1170
  • 3 de Souza A, Moloi MW. Involuntary movements due to vitamin B12 deficiency. Neurol Res 2014; 36 (12) 1121-1128
  • 4 Trakadis YJ, Alfares A, Bodamer OA. et al. Update on transcobalamin deficiency: clinical presentation, treatment and outcome. J Inherit Metab Dis 2014; 37 (03) 461-473
  • 5 Carman KB, Belgemen T, Yis U. Involuntary movements misdiagnosed as seizure during vitamin B12 treatment. Pediatr Emerg Care 2013; 29 (11) 1223-1224
  • 6 Tosun A, Aral Y, Cecen E, Aydogdu A, Cakmak BC. Involuntary movements during vitamin B12 treatment in infants. Turk J Haematol 2011; 28 (04) 317-322
  • 7 Grattan-Smith PJ, Wilcken B, Procopis PG, Wise GA. The neurological syndrome of infantile cobalamin deficiency: developmental regression and involuntary movements. Mov Disord 1997; 12 (01) 39-46
  • 8 Zanus C, Alberini E, Costa P, Colonna F, Zennaro F, Carrozzi M. Involuntary movements after correction of vitamin B12 deficiency: a video-case report. Epileptic Disord 2012; 14 (02) 174-180
  • 9 Chandra J, Jain V, Narayan S. et al. Tremors and thrombocytosis during treatment of megaloblastic anaemia. Ann Trop Paediatr 2006; 26 (02) 101-105
  • 10 Özdemir O, Baytan B, Gunes AM, Okan M. Involuntary movements during vitamin B12 treatment. J Child Neurol 2010; 25 (02) 227-230
  • 11 Mehta SH, Morgan JC, Sethi KD. Drug-induced movement disorders. Neurol Clin 2015; 33 (01) 153-174